Aesculap Biologics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1867-01-01
- Employees
- 251
- Market Cap
- -
Clinical Trials
2
Active:2
Completed:0
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)NOVOCART 3D Treatment Following Microfracture Failure
Phase 3
Active, not recruiting
- Conditions
- Articular Cartilage Defect
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Aesculap Biologics, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03219307
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Alpine Orthopaedics, North Logan, Utah, United States
NOVOCART®3D for Treatment of Articular Cartilage of the Knee
Phase 3
Active, not recruiting
- Conditions
- Articular Cartilage of the Femoral Condyle Between 2-6cm2
- Interventions
- Procedure: MicrofractureBiological: NOVOCART 3D
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Aesculap Biologics, LLC
- Target Recruit Count
- 233
- Registration Number
- NCT01957722
- Locations
- 🇺🇸
Grossmont Orthopaedic Medical Group, La Mesa, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Stanford Medicine, Redwood, California, United States
News
No news found